EcoDrugPlus

60s Ribosomal Protein L3

Ensembl ID : ENSOMEG00000017560
Gene Symbol: LOC112146277
3 Cross references
335 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSOMEG00000022770
Gene Symbol: ARAF
3 Cross references
191 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSOMEG00000003602
Gene Symbol: ABL1
3 Cross references
202 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSOMEG00000004269
Gene Symbol: ADAM17
3 Cross references
210 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSOMEG00000006372
Gene Symbol: ADAMTS5
4 Cross references
199 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSOMEG00000023045
Gene Symbol: ADRM1
1 Cross references
194 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSOMEG00000002793
Gene Symbol: ADRM1
3 Cross references
191 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSOMEG00000018416
Gene Symbol: AKT1
3 Cross references
195 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 1

Ensembl ID : ENSOMEG00000013329
Gene Symbol: ABCC1
3 Cross references
201 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 8

Ensembl ID : ENSOMEG00000023549
Gene Symbol: ABCC8
3 Cross references
224 Possible Orthologues:

Atp-Binding Cassette Sub-Family C Member 9-Like

Ensembl ID : ENSOMEG00000023674
Gene Symbol: LOC112153271
3 Cross references
231 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Alpha 1

Ensembl ID : ENSOMEG00000014366
Gene Symbol: ATP1A1
3 Cross references
215 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).